Alto Neuroscience, Inc. (ANRO) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-06

Key Insights

Ramiro Sanchez, a director of Alto Neuroscience, Inc. (ANRO), acquired 3,806 stock options on January 2, 2026 with an exercise price of $16.59 per share.
The options will vest over the course of 2026, with 952 shares vesting on March 31, 951 on June 30, 952 on September 30, and 951 on December 31, subject to Sanchez's continued service.
The options were granted to Sanchez in lieu of $45,000 in director retainer fees, suggesting the company is compensating board members through equity incentives.

Want the newest filings?

This analysis covers the filing from 2026-01-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-06

The reporting person Manji Husseini, who is a director of Alto Neuroscience, Inc. (ANRO), acquired 4,228 stock options at an exercise price of $16.59 on January 2, 2026. This could signal the director's confidence in the company's future performance.
The options granted to the director will vest over the course of 2026, with 1,057 shares vesting each quarter, indicating a long-term commitment to the company.
The options were granted as part of the company's Non-Employee Director Compensation Policy, suggesting a structured approach to incentivizing and retaining board members.

Filed: 2026-01-06

The reporting person, Christopher Nixon Cox, has been granted a stock option to purchase 7,189 shares of the issuer's common stock at an exercise price of $16.59 per share. The option will vest in four equal installments over the next year, subject to the reporting person's continued service.
The option grant appears to be part of the issuer's non-employee director compensation policy, as the exercise price is discounted to the fair market value of the stock on the grant date.
The reporting person's ownership of the issuer's securities remains at a direct ownership level, indicating no significant changes to his beneficial ownership position.

Filed: 2026-01-06

The reporting person, Gwill York, was granted a stock option to purchase 5,243 shares of the issuer's common stock, with the shares vesting quarterly over 2026.
The option was issued to York in lieu of $62,000 in retainer fees, suggesting the company is compensating directors with equity to conserve cash.
This direct ownership of company shares by a director indicates their alignment with shareholder interests and confidence in the company's long-term prospects.

Other reports for Alto Neuroscience, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.